# biote

biote is an Other based in Irving, United States.

## Overview

- **Organization type:** Other
- **Headquarters:** Irving, United States
- **Region:** North America
- **Address:** Irving, TX, United States
- **Founded:** 2012
- **Assets under management:** Undisclosed
- **Website:** biote.com

## Regulatory record

- **Reports private funds:** No

## About

biote traces its roots to 2012, when it was founded to commercialize bioidentical hormone replacement therapy (BHRT) through standardized pellet-based treatments. The company went public in 2022 via a merger with Haymaker Acquisition Corp. III, a SPAC that valued the combined entity at roughly $700 million. Under CEO Terry Weber, biote operates both a medical practice network and a direct-to-consumer diagnostic business that ships at-home test kits for hormone levels. biote's revenue model is built on recurring practitioner purchases of hormone pellets and related supplies, booking $186 million in revenue for fiscal year 2023. The company does not operate clinics itself; it trains and supplies independent medical providers — predominantly in family medicine, obstetrics and gynecology, and wellness — who then administer treatments in-office. In December 2023, biote expanded its consumer reach by launching a telehealth platform that connects patients directly with affiliated practitioners following the purchase of an at-home lab test kit. The company is headquartered in Irving, Texas, with a centralized laboratory facility that handles proprietary pellet compounding and diagnostic processing. biote exited 2023 with 965 active clinic locations and disclosed a long-term target of reaching 6,000 total locations, though quarterly growth has been uneven. The firm added 567 new providers in 2023 while churning through some existing accounts — a dynamic that reflects the challenges of medical training adoption rather than capital-allocation strategy. biote is structurally distinct from a traditional family office or investment firm: it is an operating company with its own balance sheet, R&D pipeline, and a compliance footprint governed by FDA pharmacy compounding rules and CLIA lab certification. The company's expansion rests on a licensing model — practitioners pay for training and commit to purchasing supplies exclusively from biote — which creates both high-margin recurring revenue and regulatory concentration risk if the FDA shifts its enforcement posture on compounded hormones.

## Sectors

- Healthcare Services
- Consumer Health & Wellness

## People

- Terry Weber — Chief Executive Officer

## Questions

### What does biote actually sell to medical practitioners?

biote sells proprietary bioidentical hormone pellets — small, custom-compounded subcutaneous implants — along with training on insertion technique and ongoing practice-support materials. The pellets are purchased on a recurring basis by practitioners who enroll in biote's provider network. The company does not charge a franchise fee; its revenue is generated entirely from recurring product and supply sales.

### Does biote operate its own medical clinics?

No. biote does not own or operate any physical clinics. It licenses its trademark and training to independent practitioners — primarily physicians in family medicine, obstetrics and gynecology, and wellness practices — who then buy biote-compounded hormone pellets and administer treatments to patients in their own offices.

## Related profiles

- [HyOrc Corp](https://altss.com/profile/hyorc-corp)
- [PLIANT THERAPEUTICS, INC.](https://altss.com/profile/pliant-therapeutics-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/biote-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology